Tetraneuron

Tetraneuron is a private, preclinical-stage biotech company pioneering a novel gene therapy platform targeting the E2F4 protein to address neurodegenerative diseases. The company, spun from research at Spain's prestigious Cajal Institute, is advancing a multifactorial approach aimed at reversing disease pathology. Having completed key preclinical milestones, including regulatory interactions and NHP GLP studies, and secured seed funding, Tetraneuron is positioning to advance its lead programs toward clinical development. Its strategy targets the vast, underserved market of Alzheimer's and Parkinson's diseases with a potentially disease-modifying therapy.

Gene therapy platform targeting the E2F4 protein, a transcription factor whose pathogenic phosphorylation is implicated in multiple neurodegenerative pathways. The approach uses a dominant-negative mutant variant (E2F4DN) intended to restore normal cellular function and address disease multifactorially.

Tetraneuron competes in the crowded neurodegenerative disease space against large pharma and biotechs pursuing amyloid, tau, inflammation, and other targets via antibodies, small molecules, and gene therapies. Its key differentiation is its unique, multifactorial E2F4 target, but it must demonstrate superior efficacy or safety to displace established approaches and newer modalities like antisense oligonucleotides.